Tg Therapeutics Inc (TGTX) - News Archive

New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous TreatmentRecent findings regarding BRIUMVI (ublituximab), an investi...

Stock Market Overview on May 5, 2025:On May 5, 2025, the stock market found itself in challenging waters, with several sectors and specific stocks taking noticeable hits amidst broader economic devel...

The evolving landscape of multiple sclerosis (MS) treatment continues to see significant advancements, notably the introduction of BRIUMVI (ublituximab-xiiy). The recent findings from the ENHANCE Phase 3b study offer pr...

TG Therapeutics, Inc. has recently announced various presentations that shed light on the study designs and data of BRIUMVI (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS). These pres...

TG Therapeutics, a renowned biopharmaceutical company, has announced an exciting lineup of presentations at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. This prestigious event, taking place f...

TG Therapeutics, Inc. recently announced the presentation of additional data on BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) at two major neurology conferences. The ULTIMATE I...

TG Therapeutics Presents Positive Data for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at AAN 2024 Annual MeetingTG Therapeutics, a leading biopharmaceutical company, made a significant announcement regarding the g...

TG Therapeutics, Inc. recently shared promising data from three Phase 3 trials assessing the efficacy of BRIUMVI (ublituximab-xiiy) in treating patients with relapsing forms of multiple sclerosis (RMS). The findings wer...

Investigation Reveals TG Therapeutics Positive Net Revenue in Fourth Quarter and Full Year 2023 Despite Previous LossesTG Therapeutics, a biopharmaceutical company specializing in the development of innovative treatment...

In an announcement that holds the promise to magnetize significant attention in the field of biotechnology, TG Therapeutics, Inc. has avowed a worldwide licensing pact with Precision BioSciences, Inc. The focus of this...